$VNRX News

VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript

Full Transcript: VolitionRX Q1 2026 Earnings Call

VolitionRX Q1 EPS $(0.97) Misses $(0.75) Estimate, Sales $985.076K Beat $426.600K Estimate

VolitionRx Submits Clinical Manuscript For Peer Review Over Its Nu.Q Vet Feline Prototype Assay To Trace Lymphoma In Cats

VolitionRx Announces Compliance Plan For Continued Listing Accepted By NYSE American

VolitionRx Announces Compliance Plan For Continued Listing Accepted By NYSE American

D. Boral Capital Downgrades VolitionRX to Hold

VolitionRx Launches Online Store After 10 Years Of Research Into Cancer Testing Tools, Starts Selling Lab-Ready Nucleosome Products Online To Boost Research Use

VolitionRX shares are trading lower after HC Wainwright & Co. lowered its price target on the stock from $1.5 to $1.

HC Wainwright & Co. Maintains Buy on VolitionRX, Lowers Price Target to $1

VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript

VolitionRX Q4 EPS $(0.05), Inline, Sales $447.034K Miss $765.167K Estimate

VolitionRx Secures €2 Million Funding To Advance Nu.Q Diagnostics And Expand Access In Low-Income Markets

VolitionRx Announces The Publication Of A New Clinical Manuscript Demonstrating That Nucleosome Levels, As Measured By Volition's Nu.Q H3.1 And Nu.Q H3R8 Citrulline Are Elevated In People That Have Experienced A Traumatic Event And Are Even Higher In Those Patients That Go On To Have Complications From The Trauma

VolitionRx To Highlight Use Of Its Nu.Q Cancer Assays In Management Of Lung Cancer Patients At European Lung Cancer Conference

VolitionRX shares are trading higher after the company announced it is the first to demonstrate the isolation and analysis of greater than 99% pure circulating tumor-derived DNA. The CCO said the company is in active discussions with several liquid biopsy and diagnostic companies to accelerate the development and launch of the technology as soon as possible.

VolitionRx Achieves >99% Pure Tumor-Derived DNA Isolation With Novel ChIP-Seq Liquid Biopsy Technology, Advancing Early Cancer Detection

VolitionRx Completes All Validation And Verification Of Chemiluminescent Immunoassay Version Of Nu.Q Vet Cancer Test With Fujifilm Vet Systems in Japan

VolitionRx shares are trading higher. The company announced submission of a peer-reviewed manuscript showcasing Capture-Seq and cancer biomarkers, seeking commercial partners for rapid integration.

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution